Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.
What Nicox SA’s NCX 470 presentations signal for nitric oxide–based eye therapies
Discover how Nicox SA’s NCX 470 Phase 3 data could reshape glaucoma treatment and regulatory strategy. Read the full analysis.